Citation: | CAO Zhi-qiang, LU Li, ZHANG Wei, . Immunological and preventive effects of COVID-19 vaccine against Omicron variant – a review of research progress[J]. Chinese Journal of Public Health, 2022, 38(9): 1224-1228. doi: 10.11847/zgggws1139775 |
[1] |
World Health Organization. Classification of Omicron (B. 1.1. 529): SARS-CoV-2 variant of concern[EB/OL]. (2021 – 11 – 26)[2022 – 06 – 01]. https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern.
|
[2] |
Khandia R, Singhal S, Alqahtani T, et al. Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic[J]. Environmental Research, 2022, 209: 112816. doi: 10.1016/j.envres.2022.112816
|
[3] |
Islam R, Hossain J. Detection of SARS-CoV-2 Omicron (B. 1.1. 529) variant has created panic among the people across the world: what should we do right now?[J]. Journal of Medical Virology, 2022, 94(5): 1768 – 1769. doi: 10.1002/jmv.27546
|
[4] |
香港特别行政区政府卫生署卫生防疫中心. 2019冠状病毒病死亡个案报告初步数据分析[EB/OL]. (2021 – 07 – 21)[2021 – 07 – 26]. https://www.covidvaccine.gov.hk/pdf/death_analysis.pdf.
|
[5] |
World Health Organization. Coronavirus (COVID-19) dashboard[EB/OL]. (2022 – 07 – 01)[2022 – 07 – 10]. https://covid19.who.int/?mapFilter=vaccinations.
|
[6] |
Harder T, Koch J, Vygen-Bonnet S, et al. Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021[J]. Euro Surveillance, 2021, 26(28): 2100563.
|
[7] |
Fan YJ, Chan KH, Hung IFN. Safety and efficacy of COVID-19 vaccines: a systematic review and meta-analysis of different vac-cines at phase 3[J]. Vaccines, 2021, 9(9): 989. doi: 10.3390/vaccines9090989
|
[8] |
Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression[J]. The Lancet, 2022, 399(10328): 924 – 944. doi: 10.1016/S0140-6736(22)00152-0
|
[9] |
Yu XL, Qi XR, Cao Y, et al. Three doses of an inactivation-based COVID-19 vaccine induces cross-neutralizing immunity against the SARS CoV-2 Omicron variant[J]. Emerging Microbes and Infections, 2022, 11(1): 749 – 752. doi: 10.1080/22221751.2022.2044271
|
[10] |
Wang K, Jia ZJ, Bao LL, et al. Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants[J]. Nature, 2022, 603(7903): 919 – 925. doi: 10.1038/s41586-022-04466-x
|
[11] |
Lusvarghi S, Pollett SD, Neerukonda SN, et al. SARS-CoV-2 BA. 1 variant is neutralized by vaccine booster-elicited serum but evades most convalescent serum and therapeutic antibodies[J]. Science Translational Medicine, 2022, 14(645): eabn8543. doi: 10.1126/scitranslmed.abn8543
|
[12] |
Evans JP, Zeng C, Qu PK, et al. Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2[J]. Cell Host and Microbe, 2022, doi: 10.1016/j.chom.2022.04.014.
|
[13] |
Arora P, Zhang L, Krüger N, et al. SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutraliza-tion by therapeutic antibodies[J]. Cell Host and Microbe, 2022, doi: 10.1016/j.chom.2022.04.017.
|
[14] |
Pajon R, Doria-Rose NA, Shen XY, et al. SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination[J]. The New England Journal of Medicine, 2022, 386(11): 1088 – 1091. doi: 10.1056/NEJMc2119912
|
[15] |
Bartsch YC, Tong X, Kang J, et al. Omicron variant spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines[J]. Science Translational Medicine, 2022, 14(642): eabn9243. doi: 10.1126/scitranslmed.abn9243
|
[16] |
Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A, et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA. 1 serum[J]. Cell, 2022, 185(14): 2422 – 2433.e13. doi: 10.1016/j.cell.2022.06.005
|
[17] |
Qu PK, Faraone J, Evans JP, et al. Neutralization of the SARS-CoV-2 Omicron BA. 4/5 and BA.2.12.1 subvariants[J]. The New England Journal of Medicine, 2022, 386(26): 2526 – 2528. doi: 10.1056/NEJMc2206725
|
[18] |
Clemens SAC, Weckx L, Clemens R, et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study[J]. The Lancet, 2022, 399(10324): 521 – 529. doi: 10.1016/S0140-6736(22)00094-0
|
[19] |
Pérez-Then E, Lucas C, Monteiro VS, et al. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination[J]. Nature Medicine, 2022, 28(3): 481 – 485. doi: 10.1038/s41591-022-01705-6
|
[20] |
Cheng SMS, Mok CKP, Leung YWY, et al. Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA. 1 following homologous and heterologous CoronaVac or BNT162b2 vaccination[J]. Nature Medicine, 2022, 28(3): 486 – 489. doi: 10.1038/s41591-022-01704-7
|
[21] |
Zuo FL, Abolhassani H, Du LK, et al. Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant[J]. Nature Communications, 2022, 13(1): 2670. doi: 10.1038/s41467-022-30340-5
|
[22] |
Zhao X, Zhang R, Qiao ST, et al. Omicron SARS-CoV-2 neutralization from inactivated and ZF2001 vaccines[J]. The New England Journal of Medicine, 2022, 387(3): 277 – 280. doi: 10.1056/NEJMc2206900
|
[23] |
Fendler A, Shepherd STC, Au L, et al. Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer[J]. The Lancet, 2022, 399(10328): 905 – 907. doi: 10.1016/S0140-6736(22)00147-7
|
[24] |
Zeng C, Evans JP, Chakravarthy K, et al. COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer[J]. Cancer Cell, 2022, 40(2): 117 – 119. doi: 10.1016/j.ccell.2021.12.014
|
[25] |
Alidjinou EK, Demaret J, Corroyer-Simovic B, et al. Immunogeni-city of BNT162b2 vaccine booster against SARS-CoV-2 Delta and Omicron variants in nursing home residents: a prospective obser-vational study in older adults aged from 68 to 98 years[J]. The Lancet Regional Health – Europe, 2022, 17: 100385. doi: 10.1016/j.lanepe.2022.100385
|
[26] |
Davidov Y, Indenbaum V, Tsaraf K, et al. A third dose of the BNT162b2 mRNA vaccine significantly improves immune re-sponses among liver transplant recipients[J]. Journal of Hepat-ology, 2022. doi: 10.1016/j.jhep.2022.03.042.
|
[27] |
Lee ARYB, Wong SY, Chai LYA, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis[J]. BMJ, 2022, 376: e068632.
|
[28] |
Lu L, Chen LL, Zhang RRQ, et al. Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines[J]. eBioMedicine, 2022, 79: 103986. doi: 10.1016/j.ebiom.2022.103986
|
[29] |
Ai JW, Wang X, He XY, et al. Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages[J]. Cell Host and Microbe, 2022, doi: 10.1016/j.chom.2022.05.001.
|
[30] |
Yao L, Zhu KL, Jiang XL, et al. Omicron subvariants escape antibodies elicited by vaccination and BA.2.2 infection[J]. The Lancet Infectious Diseases, 2022, 22(8): 1116 – 1117. doi: 10.1016/S1473-3099(22)00410-8
|
[31] |
Du YX, Chen L, Shi Y. Booster COVID-19 vaccination against the SARS-CoV-2 Omicron variant: a systematic review[J]. Human Vaccines and Immunotherapeutics, 2022, 18(5): 2062983. doi: 10.1080/21645515.2022.2062983
|
[32] |
Ai JW, Zhang HC, Zhang Y, et al. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost[J]. Emerging Microbes and Infections, 2022, 11(1): 337 – 343. doi: 10.1080/22221751.2021.2022440
|
[33] |
Cao YL, Yisimayi A, Jian FC, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection[J]. Nature, 2022, doi: 10.1038/s41586-022-04980-y.
|
[34] |
Wang J, Deng CGX, Liu M, et al. Four doses of the inactivated SARS-CoV-2 vaccine redistribute humoral immune responses away from the Receptor Binding Domain[J]. medRxiv, 2022, doi: 10.1101/2022.02.19.22271215.
|
[35] |
Tarke A, Coelho CH, Zhang ZL, et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron[J]. Cell, 2022, 185(5): 847 – 859.e11. doi: 10.1016/j.cell.2022.01.015
|
[36] |
Li ZW, Xiang TD, Liang BY, et al. Characterization of SARS-CoV-2-specific humoral and cellular immune responses induced by inactivated COVID-19 vaccines in a real-world setting[J]. Frontiers in Immunology, 2021, 12: 802858. doi: 10.3389/fimmu.2021.802858
|
[37] |
Wang CY, Hwang KP, Kuo HK, et al. A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants[J]. The Journal of Clinical Investiga-tion, 2022, 132(10): e157707. doi: 10.1172/JCI157707
|
[38] |
Zhang ZL, Mateus J, Coelho CH, et al. Humoral and cellular immune memory to four COVID-19 vaccines[J]. Cell, 2022, 185(14): 2434 – 2451.e17. doi: 10.1016/j.cell.2022.05.022
|
[39] |
Munro APS, Feng S, Janani L, et al. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial[J]. The Lancet Infectious Diseases, 2022, 22(8): 1131 – 1141. doi: 10.1016/S1473-3099(22)00271-7
|
[40] |
Jergović M, Uhrlaub JL, Watanabe M, et al. Competent immune responses to SARS-CoV-2 variants in older adults following two doses of mRNA vaccination[J]. Nature Communications, 2022, 13(1): 2891. doi: 10.1038/s41467-022-30617-9
|
[41] |
Parry H, Bruton R, Roberts T, et al. COVID-19 vaccines elicit robust cellular immunity and clinical protection in chronic lymphocytic leukemia[J]. Cancer Cell, 2022, 40(6): 584 – 586. doi: 10.1016/j.ccell.2022.05.001
|
[42] |
van Leeuwen LPM, Geurtsvankessel CH, Ellerbroek PM, et al. Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity[J]. The Journal of Allergy and Clinical Immunology, 2022, 149(6): 1949 – 1957. doi: 10.1016/j.jaci.2022.04.002
|
[43] |
Romero-Olmedo AJ, Schulz AR, Hochstätter S, et al. Dynamics of humoral and T-cell immunity after three BNT162b2 vaccinations in adults older than 80 years[J]. The Lancet Infectious Diseases, 2022, 22(5): 588 – 589. doi: 10.1016/S1473-3099(22)00219-5
|
[44] |
Tseng HF, Ackerson BK, Luo Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants[J]. Nature Medicine, 2022, 28(5): 1063 – 1071. doi: 10.1038/s41591-022-01753-y
|
[45] |
Jara A, Undurraga EA, Zubizarreta JR, et al. Effectiveness of CoronaVac in children 3 – 5 years of age during the SARS-CoV-2 Omicron outbreak in Chile[J]. Nature Medicine, 2022, 28(7): 1377 – 1380. doi: 10.1038/s41591-022-01874-4
|
[46] |
Andrews N, Stowe J, Kirsebom F, et al. Covid-19 vaccine effectiveness against the Omicron (B. 1.1. 529) variant[J]. The New England Journal of Medicine, 2022, 386(16): 1532 – 1546. doi: 10.1056/NEJMoa2119451
|
[47] |
Bar-On YM, Goldberg Y, Mandel M, et al. Protection by a fourth dose of BNT162b2 against Omicron in israel[J]. The New England Journal of Medicine, 2022, 386(18): 1712 – 1720. doi: 10.1056/NEJMoa2201570
|
[48] |
Magen O, Waxman JG, Makov-Assif M, et al. Fourth dose of BNT162b2 mRNA Covid-19 vaccine in a nationwide setting[J]. The New England Journal of Medicine, 2022, 386(17): 1603 – 1614. doi: 10.1056/NEJMoa2201688
|
[49] |
Collie S, Champion J, Moultrie H, et al. Effectiveness of BNT162b2 vaccine against Omicron variant in South Africa[J]. The New England Journal of Medicine, 2022, 386(5): 494 – 496. doi: 10.1056/NEJMc2119270
|
[50] |
Kirsebom F, Andrews N, Sachdeva R, et al. Effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and delta variants in England[J]. medRxiv, 2022, doi: 10.1101/2022.04.29.22274483.
|
[51] |
Accorsi EK, Britton A, Fleming-Dutra KE, et al. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and delta variants[J]. JAMA, 2022, 327(7): 639 – 651. doi: 10.1001/jama.2022.0470
|
[52] |
Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Effect of mRNA vaccine boosters against SARS-CoV-2 Omicron infection in Qatar[J]. The New England Journal of Medicine, 2022, 386(19): 1804 – 1816. doi: 10.1056/NEJMoa2200797
|
[53] |
Tartof SY, Slezak JM, Puzniak L, et al. Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study[J]. The Lancet Respiratory Medicine, 2022, 10(7): 689 – 699. doi: 10.1016/S2213-2600(22)00101-1
|
[54] |
Fleming-Dutra KE, Britton A, Shang N, et al. Association of prior BNT162b2 COVID-19 vaccination with symptomatic SARS-CoV-2 infection in children and adolescents during omicron predo-minance[J]. JAMA, 2022, 327(22): 2210 – 2219. doi: 10.1001/jama.2022.7493
|
[55] |
Cohen-Stavi CJ, Magen O, Barda N, et al. BNT162b2 vaccine effectiveness against Omicron in children 5 to 11 years of age[J]. The New England Journal of Medicine, 2022, 387(3): 227 – 236. doi: 10.1056/NEJMoa2205011
|
[56] |
Price AM, Olson SM, Newhams MM, et al. BNT162b2 protection against the Omicron variant in children and adolescents[J]. The New England Journal of Medicine, 2022, 386(20): 1899 – 1909. doi: 10.1056/NEJMoa2202826
|
[57] |
Martellucci CA, Flacco ME, Soldato G, et al. Effectiveness of COVID-19 vaccines in the general population of an Italian region before and during the Omicron wave[J]. Vaccines (Basel), 2022, 10(5): 662. doi: 10.3390/vaccines10050662
|
[58] |
McMenamin ME, Nealon J, Lin Y, et al. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study[J]. The Lancet Infectious Diseases, 2022, doi: 10.1016/S1473-3099(22)00345-0.
|
[59] |
Muhsen K, Maimon N, Mizrahi AY, et al. Association of receipt of the fourth BNT162b2 dose with omicron infection and COVID-19 hospitalizations among residents of long-term care facilities[J]. JAMA Internal Medicine, 2022, doi: 10.1001/jamainternmed.2022.2658.
|
[60] |
Puhach O, Adea K, Hulo N, et al. Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2[J]. Nature Medicine, 2022, 28(7): 1491 – 1500. doi: 10.1038/s41591-022-01816-0
|
[61] |
Baker JM, Nakayama JY, O'hegarty M, et al. SARS-CoV-2 B.1.1.529 (Omicron) variant transmission within households – Four U. S. Jurisdictions, November 2021 – February 2022[J]. MMWR Morbidity and Mortality Weekly Report, 2022, 71(9): 341 – 346. doi: 10.15585/mmwr.mm7109e1
|
[62] |
Madewell ZJ, Yang Y, Longini IM Jr, et al. Household secondary attack rates of SARS-CoV-2 by variant and vaccination status: an updated systematic review and meta-analysis[J]. JAMA Network Open, 2022, 5(4): e229317. doi: 10.1001/jamanetworkopen.2022.9317
|
[63] |
Lyngse FP, Kirkeby CT, Denwood M, et al. Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: evidence from danish households[J]. medRxiv, 2022, doi: 10.1101/2022.01.28.22270044.
|
[64] |
Jalali N, Brustad HK, Frigessi A, et al. Increased household transmission and immune escape of the SARS-CoV-2 Omicron variant compared to the Delta variant: evidence from Norwegian contact tracing and vaccination data[J]. medRxiv, 2022, doi: 10.1101/2022.02.07.22270437.
|
[65] |
World Health Organization. WHO target product profiles for COVID-19 vaccines. Revised version April 2022[EB/OL]. (2022 – 04 – 01)[2022 – 06 – 01]. https://www.who.int/publications/m/item/who-target-product-profiles-for-covid-19-vaccines.
|
[66] |
Hoffmann M, Krüger N, Schulz S, et al. The Omicron variant is highly resistant against antibody-mediated neutralization: implica-tions for control of the COVID-19 pandemic[J]. Cell, 2022, 185(3): 447 – 456.e11. doi: 10.1016/j.cell.2021.12.032
|